

What is new and relevant at CIBMTR?

Douglas Rizzo, MD MS

February 23, 2017



The CIBMTR[®] (Center for International Blood and Marrow Transplant Research[®]) is a research collaboration between the National Marrow Donor Program[®] (NMDP)/Be The Match[®] and the Medical College of Wisconsin (MCW).

Outline

- Center Outcomes analysis 2016
- Center Outcomes Forum Oct 2016
 - Progress, shared ideas, and next steps
- What is CIBMTR doing to increase accessibility to your data
 - New tools
 - Review of existing tools
- Collaborations with other organizations to collect data
 - AGNIS
 - EMR User group

Center Outcomes Report 2016



The CIBMTR[®] (Center for International Blood and Marrow Transplant Research[®]) is a research collaboration between the National Marrow Donor Program[®] (NMDP)/Be The Match[®] and the Medical College of Wisconsin (MCW).


Center Outcomes Report

Final study population - 2016

- Centers must have >90% overall f/u at 1 year
 - 2 centers closed or became inactive
- 179 US centers; 23,004 patients first allo HCT
- Primary outcome: One year survival
 - Overall: 68.9% (72.5% REL, 66.3% UNR)
- Center outcomes report 2016 includes 3 full years of data:
 - Unrelated and Related HCT 2012 – 2014
- Multivariate analysis adjusts for ‘risk factors’

How are US centers doing? 2016


Risk Adjusted Performance



- Above Expected
- As Expected
- Below Expected

Changes in category - 2016

Change from 2015 Report



What is the center outcomes forum?

- Bi-annual meeting to discuss the center specific survival analysis for hematopoietic cell transplantation (HCT) – the highest impact report produced for the Stem Cell Therapeutics Outcomes Database (SCTOD)
- 1-2 day meeting 2008, 2010, 2012, 2014, 2016
- Invitees include:
 - HCT centers/community, ASBMT Quality Outcomes Committee, biostatisticians, quality and reporting methodologists, patients, payers, National Institutes of Health/Office of Naval Research/Health Resources and Services Administration representatives
- Held in MKE, MSP
- Highly rated by attendees

5 Key Topics – Center Outcomes Forum 2016

- Measuring QOL in HCT recipients
- Possible future metrics for public reporting
- Quality improvement activities of transplant centers
- Addressing cost of care and “value”
- Handling unintended consequences of public outcomes reporting

KQ4: New quality measures?

- Develop and test a 3 year risk adjusted overall survival measure – pilot for center use
 - Work in progress: pilot testing underway for 2015 Report (HCT 2009-2013)
- Assess feasibility of collecting and reporting Patient Reported Outcomes
 - QOL pilot analysis in final manuscript phase
 - Exploring tools by which CIBMTR and centers can collect these data
 - EMR or PROMIS (NIH)

Conclusions from QOL pilot

- Feasible to prospectively collect PRO directly from patients at multiple time points
- High enrollment and return rate
- Good patient satisfaction and ongoing interest
- Baseline PROs are significantly associated with survival and post transplant QoL after adjusting for clinical factors
- Routine collection of PRO adds value to current clinical data

Can we leverage the CIBMTR data collection platform to collect PRO more routinely?

What can we do in the future?

- Explore a direct-to-patient interface to collect PRO from patients and connect those data to robust clinical data regarding their HCT
 - Use the same “core” PRO measures in all research studies of HCT patients
 - Consider core and variable measures
 - Use a system which is free, easy to access (?PROMIS ?)
 - Ensure a low burden for centers (and patients)
 - Use a single system of items which is versatile
 - Flexible, change over time

How will this help?

- Standardized, adaptable, longitudinal PRO data collection to:
 - Characterize the PRO deficits patients experience – including to plan interventions
 - Utilize patient-reported status as a more accurate and representative measure of patients' health status in multivariate analyses
 - Analyze effectiveness of various interventions across broad group of transplant centers
 - Comparison group for non-randomized interventions

High priority questions to address

- What role can centers play in data collection?
- What is the real purpose for collection of QOL
 - Research?
 - Understanding the “holistic” patient experience?
 - Public reporting?
- Do we understand Quality of Life well enough to make it publicly reportable - **NO**
- What are the unintended consequences?
- Funding \$\$\$

KQ4: New quality measures?

- Develop and test a 3 year risk adjusted overall survival measure – pilot for center use
 - Work in progress: pilot testing underway for 2015 Report (HCT 2009-2013)
- Assess feasibility of collecting and reporting Patient Reported Outcomes
 - QOL pilot analysis in final manuscript phase
 - Exploring tools by which CIBMTR and centers can collect these data
 - EMR or PROMIS (NIH)


Limitations - 2016

- Only outcome is 1 year survival
 - Only one outcome, only one year
 - Balances HCT center control, transplant approach/type of regimen, preferred long-term outcome desired by patient/society
- Is not sufficiently ‘real-time’
 - 2016 report, includes HCT 2012 – 2014
- Report issued annually
- May not ‘sufficiently’ adjust for risk factors associated with income/ SES
 - Balance challenges and benefits of data collection

3 year OS modeling

- Uses data available for the 2013 Center specific analysis – HCT years 2009-2011
- When restricted to completeness of 80% follow-up at 3 years
 - Loss of 5 centers

OS at 3 year by 1 year



Center Performance 1 vs 3 years

- All centers regardless of follow-up
- 151 (89%) no change
- 5 (3%) improve
- 13 (8%) decline

Table of p1yr by p3yr				
p1yr(1 yr model)	p3yr(3 yr model)			
Frequency	-1	0	1	Total
-1	19	3	0	22
0	8	124	2	134
1	0	5	8	13
Total	27	132	10	169

Center Performance 1 vs 3 years

- Centers with at least 80% follow-up
 - 5 centers eliminated
- 146 (89%) no change
- 5 (3%) improve
- 13 (8%) decline

Table of p1yr by p3yr

p1yr(1 yr model)	p3yr(3 yr model)			
	-1	0	1	Total
Frequency				
-1	18	3	0	21
0	8	120	2	130
1	0	5	8	13
Total	26	128	10	164

Preliminary conclusions

- 3 year follow-up represents a challenge for some centers
- Factors associated with 1 year and 3 year OS are similar
- Center performance for 1y OS and 3 y OS are similar for 90% of centers

Limitations – 3y OS metric

- Does not address ‘value’ (\$) (beyond outcome)
- Significant delay between years of HCT and the analysis
- Centers must follow patients for at least 3 years after the HCT
- Patients do not always have access to the HCT center in later years after HCT

Discussion 3y OS metric:

- Would the addition of a risk adjusted 3 y OS metric add value? **Yes**
 - To whom? **For centers but not valuable for payers**
- Are there suggestions for what would make this more valuable?

Recommendations COF 2016

Quality improvement activities

- Collaborate with FACT/ASBMT to develop QI template and planning tools
- Work with ASBMT Quality Outcomes Committee to:
 - Further refine CPA tool and data/analytics
 - Attempt to define ‘standard risk patient benchmarks’
 - Develop pre-defined dashboards for center leadership
- Consider additional tools for centers
 - Proactively monitor outcomes and predict performance
 - Visualization of data and analytics

Recommendations COF 2016

Addressing cost and value

- Remains one of the most challenging aspects to address
- Substantial drive in medicine to reduce costs while maintaining quality
 - Payer initiatives, including CMS' Oncology Care Model
- CIBMTR does not collect financial/claims data
 - Respecting benefit/burden
 - Considering partnerships to begin to address these objectives on behalf of centers
 - Agreements/permissions, completeness of data, complexities of matching patients and exchanging data

Recommendations COF 2016

Handling unintended consequences

- Robust discussion to inform centers and payers of the issues each considers important and values
- Dispel misunderstandings about the CIBMTR Center Outcomes Analysis
- Payers want:
 - To assure their clients of high quality, consistent access
 - Contract with a ‘reasonable’ number of centers
 - Stability and predictable financial risk
 - Autologous reporting
 - “Value”

Recommendations COF 2016

Handling unintended consequences

- Centers want:
 - Stability
 - Consistent access on behalf of the patients they serve
 - Consideration/adjustment of highest risk patients and allow development of innovations that move the field (eg cord blood, haplo-identical)
 - NIH-funded research to improve next generation of outcomes
 - A reasonable appeal process that accomodates a single year's "under-performance"
 - Transparency of purpose and intent

A 'super-massive' black hole




How can centers get information back from CIBMTR?

- Publications
- Website
- Summary slides
- Information requests
- Calculators
 - Disease Risk Index, One year survival calculator
- CIBMTR Portal
 - eDBTC – electronic Data Back to Centers
 - Center performance analytics

Summary Slides – HCT Trends and Survival Data


- An annual report on data submitted to the CIBMTR by centers worldwide
- Describes information related to practices and general survival outcomes after hematopoietic cell transplantation

Annual Number of Transplant Recipients in the US by Transplant Type




*2014 Data incomplete 3

Allogeneic Transplant Recipients in the US, by Donor Type



*2014 Data incomplete 4

Survival after HLA Match Sibling Donor Transplants for AML, 2003-2013



By Disease Status 17

Disease Risk Index (DRI) Calculator

- The Disease Risk Index (DRI) is a validated tool to categorize groups of patients undergoing allogeneic stem cell transplantation (HCT) for **hematologic malignancy** by disease risk. It is intended for research purposes, to stratify patients in broad disease risk categories for retrospective or prospective studies.
- The DRI considers only disease-related parameters (i.e., disease, stage and, for some diseases, cytogenetics) and was developed only for the primary outcome of **overall survival** after HCT.

[Publication Details](#)

DRI Assignment Tool

Disease*:

Disease Stage*:


DRI Group:

CIBMTR Portal – Tools for Centers



The CIBMTR[®] (Center for International Blood and Marrow Transplant Research[®]) is a research collaboration between the National Marrow Donor Program[®] (NMDP)/Be The Match[®] and the Medical College of Wisconsin (MCW).

CIBMTR Portal



The screenshot shows the CIBMTR Portal homepage. At the top, there is a green navigation bar with the text "CIBMTR Portal" on the left and "Sign In" with a gear icon and a question mark icon on the right. Below the navigation bar, there is a grey bar with "BROWSE" and "PAGE" links. The main content area features the CIBMTR logo on the left, which consists of two overlapping circles (one green, one blue) and the text "CIBMTR® CENTER FOR INTERNATIONAL BLOOD & MARROW TRANSPLANT RESEARCH". To the right of the logo is a search bar with the placeholder text "Search this site" and a magnifying glass icon. Below the search bar, there is a red button with the Google+ logo and the text "Sign in with Google". The main content area also contains a heading "Welcome to the CIBMTR Portal" followed by a paragraph explaining the portal's purpose and a list of applications. At the bottom of the main content area, there is a paragraph stating that users must have a Google account registered with the CIBMTR.

CIBMTR Portal

Sign In

BROWSE PAGE

 CIBMTR®
CENTER FOR INTERNATIONAL BLOOD
& MARROW TRANSPLANT RESEARCH

Search this site

Welcome to the CIBMTR Portal

The CIBMTR Portal is a specialized and secure, password-protected area for CIBMTR community users. As an authorized user, you may view, analyze, or download information for your center by accessing different applications:

- **CVDR (Center Volumes Data Report)** – View details regarding your center’s transplant volume in prior years.
- **Survival Calculator** – Create a one-year predicted survival for allogeneic transplants based on the three year transplant center specific survival dataset.
 - This application is only available to Medical Directors, Physicians, and Center Administrators.
- **DBtC (Data Back to Centers)** – Access TED-level data your center submitted through FormsNet.
- **eDBtC (enhanced Data Back to Centers)** – Analyze, filter, or download select center CRF- and TED-level data from 2008 to present.
- **CPA (Center Performance Analytics)** – Comparatively analyze your transplant center specific survival data relative to aggregated data from other US centers.

To access the Portal and its applications, you must have a Google account registered with the CIBMTR.

 Sign in with Google


Data Back to Centers (DBtC)

- Originally introduced in 2009
- Provides validated data to centers from CIBMTR Database
- Includes Pre-TED (2400) and Post-TED (2450) data or equivalents from CRF forms:
 - FormsNet as well as legacy IBMTR & NMDP data (pre-December 2007)
 - Both allogeneic and autologous transplant data
 - US and international centers
- Accessible on the CIBMTR Portal
- Refreshed quarterly
- Downloadable file in comma separated values (.csv) file
- Paired with data dictionary

eDBtC (enhanced DBtC) using Qlikview

- Dramatically improved user interface
- Self service and easy access
- Visualization of center analytics and descriptive statistics
 - ~60 selectable data dimensions, TED and CRF variables
 - ~30 predefined filters
- Logical organization of data in tabs
- Ad Hoc analysis – explore your data, **including outcomes**
- Data will be refreshed monthly
- Export application source data will be retained on the CIBMTR Portal Site
- Current DBtC data download capability retained

eDBtC Patient Level Data



eDBtC: Planned this year

- Data for RFI – Demonstrated at Tandem
 - A tool for centers to support completion of their ASBMT RFI
 - Leverages eDBtC data
 - Support for clinical and survival statistics
- Enhanced features & more data in eDBtC
 - New filters and data to Ad Hoc query tab
 - Add Sub-disease groups to Disease tab
 - Cytogenetics
 - GVHD Prophylaxis– common drug combinations
 - HLA match information for unrelated donors

Survival Calculator – 1 year

- Calculates probability of 1 year survival after allogeneic transplantation for individual patients
- Uses model developed for annual center-specific outcomes analysis for US transplant centers

The screenshot shows the CIBMTR Portal interface for the Patient One Year Survival Probability Calculator. The page is titled "Patient One Year Survival Probability Calculator" and is divided into several sections for data entry:

- RECIPIENT CHARACTERISTICS:** Recipient Age, Recipient Gender, Recipient Race/Ethnicity, Recipient CMV Status, Karnofsky/Lansky Score at Transplant, and HCT-CI Comorbidity Score.
- DISEASE CHARACTERISTICS:** Disease.
- TRANSPLANT CHARACTERISTICS:** Prior Autologous Transplant and Graft Type.
- DONOR CHARACTERISTICS:** (Fields are not visible).

Below the input fields, there is a "Clear" button and a "Submit" button. A red asterisk indicates that all fields are required. The results section shows a "Predicted Patient One Year Survival Probability Estimate" of 0 and a "95% confidence interval for survival probability" of 0-0. A note explains that this represents the confidence limit for one year survival probability for a population of patients with the characteristics listed above transplanted in the US between 2009 and 2011.

This calculator uses aggregate data from US HCT centers to provide an estimate of one year survival for patients for whom a first allogeneic HCT is planned. While these estimates are accurate for a group of patients, individual outcomes may vary from those predicted by this tool. This tool does not include centers' outcome performance in the calculation of predicted one year survival. Other factors unmeasured in the center outcomes analysis may affect the actual probability of survival. Similarly, because of the ever-changing nature of the field of transplantation, use of previous year's survival data may not completely reproduce predicted survival as new approaches to HCT emerge. Finally, the purpose of this tool is to provide centers with estimates of one year survival to inform decision making and plan program resources to support patients, rather than to restrict access to HCT per se. Because of the complexities of transplantation and the requirements for explanation, this tool is currently not provided for use directly by patients.

CIBMTR IT

What can centers expect in Center Performance Analytics (CPA)?

- ✓ Selectable data dimensions include key variables for first allogeneic transplants facilitated in the U.S. in 2011, 2012 & 2013
- ✓ Data is organized in category-specific tabs
- ✓ Predefined filters enable limited comparative analysis based on *center size, patient population (adult, pediatric, both), center performance, and region*
- ✓ Visualization of each center's data relative to other centers in data set for selected dimensions
- ✓ Analyze center's own one-year observed survival rate
- ✓ Create center-specific query on data dimensions available in the data set
- ✓ Export filtered data in Excel file format
- ✓ Export the center's entire Center Specific data set
- ✓ Data refreshed annually

Selectable Dimensions in CPA

Patient	Disease	Transplant	Outcomes
<ul style="list-style-type: none"> ▪ Age Group ▪ Gender ▪ HCT CI ▪ History of Malignancy ▪ KPS Category Score ▪ KPS Score ▪ Race ▪ Recipient CMV Status 	<ul style="list-style-type: none"> ▪ Broad Disease ▪ Disease stage ▪ ALL Philadelphia chromosome ▪ ALL T-cell lineage ▪ CLL & other chronic Leukemia stage ▪ NHL subtype ▪ HL Chemo sensitivity ▪ NHL Chemo Sensitivity ▪ Interval Between DX & TX 	<ul style="list-style-type: none"> ▪ Year of Transplant ▪ Product Type ▪ Donor Type/Graft Type/HLA ▪ Product Type Details ▪ BM or PBSC HLA Match ▪ Single Cord Blood HLA Match ▪ Conditioning Regimen Drugs ▪ TBI ▪ Prior Auto HCT ▪ BM or PB donor Age at Transplant ▪ BM or PB donor CMV status ▪ BM or PB donor Race/ethnicity Match ▪ BM or PB donor Parity ▪ BM or PB donor Sex ▪ BM or PB donor Sex Match 	<ul style="list-style-type: none"> ▪ One year Survival Probability
<p>Ad-hoc Query</p>			

Center Performance Analytics

To Make Selections

To make a selection click on the data value you want to know more about. The selected data value turns green. Values compatible with the selection are white and unrelated values are gray.
To select more than one item in the same listbox, hold the CTRL key down while selecting additional values.

Selected Data (Green)	Quarter		Month		
Associated Data (White)	Q1	Jan	Feb	Mar	
Unrelated Data (Gray)	Q2	Apr	May	Jun	
	Q3	Jul	Aug	Sep	
	Q4	Oct	Nov	Dec	

Clear Selections

To clear all selections click on the "Clear" button from the tool bar.

To clear selections in a specific field, click the eraser icon on the list box.



Search

Click on list box title bar, or click the magnifier icon. Start typing the value or number you wish to find. Press enter or click on a value to select. Also, use a search object.


Title Bar >> Week

1	2	3	4	5
6	7	8	9	10
11	12	13	14	15

Search: Search

Minimized Icons

Double click on minimized icons to launch. Hover with cursor over minimized icon to view entire title.



Cycle & Drill Buttons

If available, click on cycle button to display other dimensions, or drill down button to drill down to the next variable in the chart.

Cycle	XL	Drilldown	XL
Sales	1,783,148	Sales	1,783,148
	1,783,148		1,783,148

Printing and Exporting

Click the corresponding icon at the top right of the window.
(To print click to export click)

To Navigate Between Sheets

To move between sheets click on the sheets tab at the top.



Center Performance Analytics

Intro | How To | **Patient** | Disease | Transplant | Outcomes | Ad-hoc Query | Data Download

Patient *single center not specified* Year 2011 | 2012 | 2013 Welcome MCWCORP\drizzo [Clear All Selections](#)

Current Selections



[Show All Centers](#)

Comparison Filters

Center Size

- 1 to 30
- 31 to 70
- 71 to 120
- 121 to 220
- >220

Pediatric vs Adult

- Adults
- Both
- Peds

Region

- Region 1: Northeast (Divisions 1 and 2)
- Region 2: Midwest (Divisions 3 and 4)
- Region 3: South (Divisions 5)
- Region 4: West (Divisions 8 and 9)

Center Performance

As expected in 2014 and 2015 reports
Better than expected in 2014 and 2015 reports

Total N Transplants: 22,174 (based on filter selections)
You are viewing data for Center: -

- Dimension Selector**
- Age Group
 - Gender
 - HCT CI
 - History of Malignancy
 - KPS Category Score
 - KPS Score
 - Race
 - Recipient CMV Status

Center: -

Age Group	HCT CI	0	1	2	3	4	5
0 to 9		1684 cases 21% of 0 76% of 0 to 9 8% of total	266 cases 9% of 1 12% of 0 to 9 1% of total	81 cases 3% of 2 4% of 0 to 9 0% of total	115 cases 3% of 3 5% of 0 to 9 1% of total	44 cases 2% of 4 2% of 0 to 9 0% of total	13 cases 1% of 5 1% of 0 0% of total
10 to 19		1020 cases 13% of 0 57% of 10 to 19 5% of total	265 cases 8% of 1 15% of 10 to 19 1% of total	157 cases 5% of 2 9% of 10 to 19 1% of total	178 cases 5% of 3 10% of 10 to 19 1% of total	84 cases 4% of 4 5% of 10 to 19 0% of total	35 cases 3% of 5 2% of 10 0% of total
20 to 29		696 cases 9% of 0 36% of 20 to 29 3% of total	238 cases 8% of 1 12% of 20 to 29 1% of total	286 cases 10% of 2 15% of 20 to 29 1% of total	351 cases 10% of 3 18% of 20 to 29 2% of total	169 cases 8% of 4 9% of 20 to 29 1% of total	81 cases 8% of 5 4% of 20 0% of total
30 to 39		726 cases 9% of 0 35% of 30 to 39 3% of total	298 cases 10% of 1 14% of 30 to 39 1% of total	327 cases 11% of 2 16% of 30 to 39 1% of total	361 cases 10% of 3 17% of 30 to 39 2% of total	199 cases 10% of 4 10% of 30 to 39 1% of total	78 cases 7% of 5 4% of 30 0% of total

Comparison Centers

Age Group	HCT CI	0	1	2	3	4
0 to 9		3368 cases 8% of 0 8% of 0 to 9 8% of total	532 cases 1% of 1 1% of 0 to 9 1% of total	162 cases 0% of 2 0% of 0 to 9 0% of total	230 cases 1% of 3 1% of 0 to 9 1% of total	88 cases 0% of 4 0% of 0 to 9 0% of total
10 to 19		2040 cases 5% of 0 5% of 10 to 19 5% of total	530 cases 1% of 1 1% of 10 to 19 1% of total	314 cases 1% of 2 1% of 10 to 19 1% of total	356 cases 1% of 3 1% of 10 to 19 1% of total	168 cases 0% of 4 0% of 10 to 19 0% of total
20 to 29		1392 cases 3% of 0 3% of 20 to 29 3% of total	476 cases 1% of 1 1% of 20 to 29 1% of total	572 cases 1% of 2 1% of 20 to 29 1% of total	702 cases 2% of 3 2% of 20 to 29 2% of total	338 cases 1% of 4 1% of 20 to 29 1% of total
30 to 39		1452 cases 3% of 0 3% of 30 to 39 3% of total	596 cases 1% of 1 1% of 30 to 39 1% of total	654 cases 1% of 2 1% of 30 to 39 1% of total	722 cases 2% of 3 2% of 30 to 39 2% of total	398 cases 1% of 4 1% of 30 to 39 1% of total

Center Performance Analytics

Patient

single center not specified

Current Selections

Center Volume 121 to 220



Show All Centers

Comparison Filters

Center Size

1 to 30
31 to 70
71 to 120
121 to 220
>220

Pediatric vs Adult

Adults
Both
Peds

Region

Region 1: Northeast (Divisions 1 and 2)
Region 2: Midwest (Divisions 3 and 4)
Region 3: South (Divisions 5
Region 4: West (Divisions 8 and 9)

Center Performance

As expected in 2014 and 2015 reports
Better than expected in 2014 and 2015 reports

Total N Transplants: 22,174 (based on filter selections)

You are viewing data for Center: -

Dimension Selector

- Age Group
- Gender
- HCT CI

Center: -

*HCT CI	% Transplants	Count
	100.00%	22174
0	36.46%	8084
1	14.08%	3122
2	13.33%	2955
3	15.86%	3516
4	9.10%	2017
5	4.87%	1080
6	2.98%	660
7	1.42%	315
8	0.77%	170
9	0.36%	80
10	0.18%	41
11	0.02%	5
12	0.03%	6
13	0.00%	1
14	0.00%	1
999	0.55%	121

Comparison Centers

*HCT CI	% Transplants	count
	100.00%	9402
0	32.95%	3098
1	13.64%	1282
2	14.64%	1376
3	17.08%	1606
4	9.49%	892
5	5.21%	490
6	3.08%	290
7	1.57%	148
8	0.94%	88
9	0.40%	38
10	0.21%	20
12	0.04%	4
999	0.74%	70

Center Performance Analytics – Query Tool

Intro How To Patient Disease Transplant Outcomes **Ad-hoc Query** Data Download

Ad-hoc Query *single center not specified*

Current Selections 10128



Patient

- Recipient Sex
- Recipient Age Group
- Adult Indicator
- Recipient Race
- Karnofsky Score at T...
- Sorrow Comorbidity S...
- Sorrow Comorbidity S...
- Recipient CMV Status

Disease

- AML Disease Status ...
- ALL Disease Status a...
- ALL T-cell lineage
- ALL Philadelphia chr...
- CML Disease Status ...
- CML Cytogenetic CR
- CML Molecular CR
- al_stat_grp
- CLL PCL and other s...

HCT

- yearbx
- Prior Auto HCT
- Product Type
- Product Type Details
- Multiple Cord Blood ...
- Conditioning Regime...
- Total Body Irradiation
- Conditioning Regime...
- related

Outcomes

- Patient Alive at Last Contact
- Survival Status Known at 1 Year
- Dead at 1 year

Total N Transplants: 22,174 (based on filter selections)
 You are viewing data for Center: -

Clear Report Selections

Dimension Selector

- Age Group
- Race
- Gender
- KPS Score
- KPS Category Score
- HCT CI
- Recipient CMV Status
- History of Malignancy
- Broad Disease
- Disease Stage
- ALL T-cell lineage
- ALL Philadelphia chromosome
- CLL PCL and other chronic Leukemia st...
- NHL chemotherapy sensitivity
- HL chemotherapy sensitivity
- NHL subtype
- Prior Auto HCT
- Year of Transplant
- Product Type
- Product Type Details
- Total Body Irradiation
- Conditioning Regimen Drugs
- BM or PBSC Donor HLA match
- Single Cord Blood HLA Match
- Multi Cord Blood HLA Match
- BM or PB Donor Sex
- BM or PB Donor Sex Match
- BM or PB donor Age at Transplant
- BM or PB Donor Race/Ethnicity
- BM or PB Donor CMV Status
- BM or PB Donor Parity
- Donor Type/Graft Type/HLA

Custom Report

Transplants	% Transplants
22,174	100.00%
22,174	100.00%

Center Performance Analytics -Query

Intro How To Patient Disease Transplant Outcomes **Ad-hoc Query** Data Download

Ad-hoc Query *single center not specified* Year 2011 20

Current Selections
Center Volume 121 to 220



Patient

Recipient Sex
 Recipient Age Group
 Adult Indicator
 Recipient Race
 Karnofsky Score at T...
 Sorrow Comorbidity S...
 Sorrow Comorbidity S...
 Recipient CMV Status

Disease

AML Disease Status ...
 ALL Disease Status a...
 All T-cell lineage
 ALL Philadelphia chr...
 CML Disease Status ...
 CML Cytogenetic CR
 CML Molecular CR
 al_stat_grp
 CLL, DCV and other s...

HCT

yearbx
 Prior Auto HCT
 Product Type
 Product Type Details
 Multiple Cord Blood ...
 Conditioning Regime...
 Total Body Irradiation
 Conditioning Regime...
 related

Outcomes

Patient Alive at Last Contact
 Survival Status Known at 1 Year
 Dead at 1 year

Dimension Selector

- Age Group
- Gender
- HCT CI
- History of Malignancy
- KPS Category Score
- KPS Score
- Race
- Recipient CMV Status


Total N Transplants: 22,174 (based on filter selections)
 You are viewing data for Center: -

Clear Report Selections

Custom Report

Age Group	Gender	HCT CI	Transplants	% Transplants
			4,701	100.00%
0 to 9	Female	0	193	4.11%
0 to 9	Female	1	27	0.57%
0 to 9	Female	2	12	0.26%
0 to 9	Female	3	12	0.26%
0 to 9	Female	4	5	0.11%
0 to 9	Female	5	3	0.06%
0 to 9	Female	6	2	0.04%
0 to 9	Female	9	1	0.02%
0 to 9	Male	0	257	5.47%
0 to 9	Male	1	42	0.89%
0 to 9	Male	2	8	0.17%
0 to 9	Male	3	17	0.36%
0 to 9	Male	4	6	0.13%
0 to 9	Male	5	3	0.06%
0 to 9	Male	6	2	0.04%
0 to 9	Male	999	1	0.02%
10 to 19	Female	0	108	2.30%
10 to 19	Female	1	27	0.57%
10 to 19	Female	2	17	0.36%
10 to 19	Female	3	13	0.28%
10 to 19	Female	4	8	0.17%
10 to 19	Female	5	4	0.09%
10 to 19	Female	7	2	0.04%
10 to 19	Female	8	1	0.02%
10 to 19	Female	10	1	0.02%
10 to 19	Male	0	129	2.74%
10 to 19	Male	1	39	0.83%
10 to 19	Male	2	23	0.49%
10 to 19	Male	3	36	0.77%
10 to 19	Male	4	11	0.23%
10 to 19	Male	5	4	0.09%
10 to 19	Male	6	3	0.06%
10 to 19	Male	7	3	0.06%
10 to 19	Male	8	1	0.02%
20 to 29	Female	0	53	1.13%
20 to 29	Female	1	18	0.38%
20 to 29	Female	2	28	0.60%
20 to 29	Female	3	39	0.83%

Center Performance Analytics - Outcomes



Center Performance Analytics



CPA platform – What's next?

- Together with DBtC/eDBTC, provides more useful data and analytics for centers
- Launched April 2016
- Future iterations with additional relevant demographic data
 - GVHD prophylaxis, graft manipulation, trials participation, etc
- Additional outcomes possible – NOT adjusted
 - Survival later than one year
 - Acute and chronic GVHD
- Suggestions welcome

Introducing a new RFI tool

Accessing the new RFI tool

- Accessible through eDBtC from the Center Dashboard or the Disease tabs (top right corner “ASBMT RFI” button).
- Only available to active, U.S.-based centers.
- Application embedded into the Qlikview® eDBtC application.
- Separate, independent filtering configuration that allows users to switch between eDBtC and the RFI module without having to clear or reconfigure filter variables.

Current Selections
 Karnofsky Sc... 20
 HCT-CI-Arrh... False



Clear Selections

Patient

- Age Group at Transplant: 30-39
- Patient Gender: Female
- Patient Race: White/Caucasian
- Karnofsky Score: 20
- HCT-CI Score: 0
- HCT-CI-Arrhythmia: False
- HCT-CI-Cardiac: False

Disease

- AML
- CML
- AID

Transplant

- ALLO - Allogeneic
- AUTO - Autologous
- Preparative Regimen:
- Conditioning Intensity: Unknown
- Transplant Number:
- Prior Transplant: Yes
- Transplant Type: ALLO - Allogeneic
- Cell Source: Peripheral blood

Donor-Related (Allo only)


- Donor Type: Other relative - matching unkn...
- D-R Sex Match: F-F
- D-R CMV Status: Unknown
- D-R ABO Match:

Outcomes

- Patient Status at Last Contact: Dead

Total N Patients: 2 (based on filter selections)
 Total N Transplants: 3 (based on filter selections)

- Number of Transplants
- Number of Patients
- Center Numbers
- Patient Age at Transplant
- Cell Source**
- HCT-CI Score
- Disease
- Conditioning Intensity



RFI tool features

- Three separate tabbed interfaces that contain Survival Statistics by Disease, Clinical Statistics, and Patient Level data.
- Survival Statistics (tab) allows for Table and Pivot views for record level and aggregated data consumption (green “Pivot View/Table View” button at top above the data table).
- Allows users to print or export data to Excel spreadsheet.

ASBMT RFI Survival Statistics by Disease

Search

eDBtC

Current Selections

RFI_Final.TR... - Allogeneic



Clear All Selections

Report Category

Allogeneic, Myeloablative, Related Donor, ≥ 1 Antigen Mismatch
 Allogeneic, Myeloablative, Related Donor, 0 Antigen Mismatch
 Allogeneic, Myeloablative, Unrelated Donor, 0 Antigen Mismatch

Adult-Pediatric Indicator

Adult

Transplant Type

Allogeneic
 Autologous

Diagnosis

AML and ALL
 CLL
 CML
 Hodgkin's Disease

Disease Detail

Disease Name

Donor Type

Cord Blood Donor
 Related Donor

Conditioning Intensity

Myeloablative
 Non-Myeloablative

HLA Match

> 1 Antigen Mismatch
 ≥ 1 Antigen Mismatch

Pivot View

Survival Statistics

Adult-Pediatric Patient	Transplant Type	Diagnosis	Disease Detail	Risk	Donor Type	Conditioning	HLA Match	2013 Total Count N	2013 100D Survival N	2013 1Y Survival N	2014 Total Count N	2014 1Y Survival N
Adult	Allogeneic	AML and ALL	-	High risk	Related Donor	Myeloablative	≥ 1 Antigen Mismatch	0	0	0	1	0
Adult	Allogeneic	AML and ALL	-	High risk	Related Donor	Myeloablative	0 Antigen Mismatch	0	0	0	1	0
Adult	Allogeneic	AML and ALL	-	High risk	Related Donor	Non-Myeloablative	≥ 1 Antigen Mismatch	0	0	0	0	0
Adult	Allogeneic	AML and ALL	-	High risk	Related Donor	Non-Myeloablative	0 Antigen Mismatch	0	0	0	2	0
Adult	Allogeneic	AML and ALL	-	High risk	Unrelated Donor	Myeloablative	0 Antigen Mismatch	1	1	0	1	0
Adult	Allogeneic	AML and ALL	-	High risk	Unrelated Donor	Myeloablative	1 Antigen Mismatch	1	1	0	0	0
Adult	Allogeneic	AML and ALL	-	High risk	Unrelated Donor	Non-Myeloablative	0 Antigen Mismatch	0	0	0	0	0
Adult	Allogeneic	AML and ALL	-	Intermediate risk	Related Donor	Myeloablative	≥ 1 Antigen Mismatch	0	0	0	0	0
Adult	Allogeneic	AML and ALL	-	Intermediate risk	Related Donor	Myeloablative	0 Antigen Mismatch	2	2	1	2	1
Adult	Allogeneic	AML and ALL	-	Intermediate risk	Related Donor	Non-Myeloablative	≥ 1 Antigen Mismatch	0	0	0	0	0
Adult	Allogeneic	AML and ALL	-	Intermediate risk	Related Donor	Non-Myeloablative	0 Antigen Mismatch	2	2	1	1	1
Adult	Allogeneic	AML and ALL	-	Intermediate risk	Unrelated Donor	Myeloablative	0 Antigen Mismatch	1	1	1	3	1
Adult	Allogeneic	AML and ALL	-	Intermediate risk	Unrelated Donor	Myeloablative	1 Antigen Mismatch	1	1	1	0	0
Adult	Allogeneic	AML and ALL	-	Intermediate risk	Unrelated Donor	Non-Myeloablative	0 Antigen Mismatch	3	3	3	1	1
Adult	Allogeneic	AML and ALL	-	Intermediate risk	Unrelated Donor	Non-Myeloablative	1 Antigen Mismatch	1	1	1	0	0
Adult	Allogeneic	AML and ALL	-	Low risk	Cord Blood Donor	Non-Myeloablative	> 1 Antigen Mismatch	0	0	0	1	0
Adult	Allogeneic	AML and ALL	-	Low risk	Related Donor	Myeloablative	≥ 1 Antigen Mismatch	0	0	0	5	0
Adult	Allogeneic	AML and ALL	-	Low risk	Related Donor	Myeloablative	0 Antigen Mismatch	10	10	7	7	7
Adult	Allogeneic	AML and ALL	-	Low risk	Related Donor	Non-Myeloablative	≥ 1 Antigen Mismatch	2	2	1	1	1

* CIBMTR does not use "antigen" level typing as indicated on the RFI, but uses "Allele" level typing to determine HLA match grade.

* Survival calculations based on ASBMT specifications.

* Caution: This application allows you to view data that you have provided to CIBMTR. CIBMTR does not collect every variable required for your RFI submission, for example, CIBMTR does not collect length of stay or lost to follow up. Discrepancies in RFI data can only be determined and corrected by the center. Centers are strongly encouraged to review this data for accuracy and completeness before using these data for inclusion in the RFI.

ASBMT RFI Survival Statistics by Disease

Search

eDBtC

Current Selections

RFI_Final.TR... Allogeneic



Clear All Selections

Report Category

- Allogeneic, Myeloablative, Related Donor, ≥ 1 Antigen Mismatch
- Allogeneic, Myeloablative, Related Donor, 0 Antigen Mismatch
- Allogeneic, Myeloablative, Unrelated Donor, 0 Antigen Mismatch

Adult-Pediatric Indicator

Adult

Transplant Type

- Allogeneic**
- Autologous

Diagnosis

- AML and ALL
- CLL
- CML
- Hodgkin's Disease

Disease Detail

Disease Name

Donor Type

- Cord Blood Donor
- Related Donor

Conditioning Intensity

- Myeloablative
- Non-Myeloablative

HLA Match

- > 1 Antigen Mismatch
- ≥ 1 Antigen Mismatch

Survival Statistics

Adult-Pediatric Patient	Transplant Type	Diagnosis	Solid Tumor, Non-Malignant	Risk	Donor Type	Conditioning	HLA Match	2013 100 Day	2013 1 Year	2013 Total	2014 100 Day	2014 1 Year	2014 Total
Adult	Allogeneic	AML and ALL	-	High risk	Related Donor	Myeloablative	≥ 1 Antigen Mismatch	0	0	0	1	1	2
						Myeloablative	0 Antigen Mismatch	0	0	0	1	1	2
						Non-Myeloablative	≥ 1 Antigen Mismatch	0	0	0	0	0	0
					Unrelated Donor	Myeloablative	0 Antigen Mismatch	1	0	1	1	0	0
						Myeloablative	1 Antigen Mismatch	1	0	1	0	0	0
						Non-Myeloablative	0 Antigen Mismatch	0	0	0	0	0	0
				Intermediate risk	Related Donor	Myeloablative	≥ 1 Antigen Mismatch	0	0	0	0	0	0
						Myeloablative	0 Antigen Mismatch	2	1	2	2	1	3
						Non-Myeloablative	≥ 1 Antigen Mismatch	0	0	0	0	0	0
					Unrelated Donor	Myeloablative	0 Antigen Mismatch	2	1	2	1	1	3
						Myeloablative	1 Antigen Mismatch	1	1	1	0	0	2
						Non-Myeloablative	0 Antigen Mismatch	1	1	1	3	1	4
Cord Blood Donor	Non-Myeloablative	> 1 Antigen Mismatch	0	0	0	0	0	0					
Related Donor	Myeloablative	≥ 1 Antigen Mismatch	0	0	0	5	3	8					
	Myeloablative	0 Antigen Mismatch	10	7	10	7	6	17					
					Non-Myeloablative	≥ 1 Antigen Mismatch	2	1	2	1	1	3	

* CIBMTR does not use "antigen" level typing as indicated on the RFI, but uses "Allele" level typing to determine HLA match grade.
 * Survival calculations based on ASBMT specifications.
 * Caution: This application allows you to view data that you have provided to CIBMTR. CIBMTR does not collect every variable required for your RFI submission, for example, CIBMTR does not collect length of stay or lost to follow up. Discrepancies in RFI data can only be determined and corrected by the center. Centers are strongly encouraged to review this data for accuracy and completeness before using these data for inclusion in the RFI.

ASBMT RFI Clinical Statistics

Search

eDBtC

Current Selections



Clear All Selections

Adult-Pediatric Indicator

Adult

Transplant Type

Allogeneic
Autologous

Conditioning Regimen

Myeloablative
Non-Myeloablative

Donor Type

Cord Blood Donor
Related Donor
Unrelated Donor

HLA Match

> 1 Antigen Mismatch
≥ 1 Antigen Mismatch
0 Antigen Mismatch
1 Antigen Mismatch

Clinical Statistics

Transplant Type	Conditioning Regimen	Donor Type	HLA Match	2013 Total Count N	2013 100D Survival N	2013 1Y Survival N	2014 Total Count N	2014 100D Survival N	2014
Allogeneic	Myeloablative	Related Donor	≥ 1 Antigen Mismatch	0	0	0	6	6	
			0 Antigen Mismatch	20	20	14	17	17	
			Total	20	20	14	23	23	
		Unrelated Donor	0 Antigen Mismatch	18	17	15	18	17	
			1 Antigen Mismatch	3	3	2	0	0	
	Total	21	20	17	18	17			
	Non-Myeloablative	Cord Blood Donor	> 1 Antigen Mismatch	0	0	0	1	0	
			Total	0	0	0	1	0	
		Related Donor	≥ 1 Antigen Mismatch	2	2	1	6	5	
			0 Antigen Mismatch	11	10	9	19	14	
Total			13	12	10	25	19		
Unrelated Donor	0 Antigen Mismatch	7	7	7	12	12			
	1 Antigen Mismatch	2	2	1	1	1			
Total	9	9	8	13	13				
Total	22	21	18	39	32				
Autologous	-	-	Total	63	61	49	80	72	
				126	125	113	135	133	
			Total	126	125	113	135	133	
Total	126	125	113	135	133				
Total	189	186	162	215	205				

* CIBMTR does not use "antigen" level typing as indicated on the RFI, but uses "Allele" level typing to determine HLA match grade.

* Caution: This application allows you to view data that you have provided to CIBMTR. CIBMTR does not collect every variable required for your RFI submission, for example, CIBMTR does not collect length of stay or lost to follow up. Discrepancies in RFI data can only be determined and corrected by the center. Centers are strongly encouraged to review this data for accuracy and completeness before using these data for inclusion in the RFI.

RFI additional features

- Users also have the ability to drill-down into their data, applying filters by clicking on data values within the data grid(s).
- Data can be exported in ASBMT RFI format from the Patient Level Data tab (“ASBMT RFI Export” button in upper right hand corner).

ASBMT RFI Patient Level Data

Search

eDBtC

Current Selections



Clear All Selections

Adult-Pediatric Indicator

Adult

Transplant Type

Allogeneic
Autologous

Diagnosis

AML and ALL
CLL
CML
Hodgkin's Disease
MDS
Myeloma/PCD
Neuroblastoma

Transplant Not Counted Reason

Missing HLA-Matching
Unknown Risk
Unknown Risk; Missing Donor Type; Missing Conditionin...
Unknown Risk; Missing HLA-Matching

ASBMT RFI Export

RFI Patient Level Data

Adult-Pediatric Indicator	CRID	Year of Transplant	Transplant Date	Transplant Number	Transplant Type	Donor Relationship	HLA Match	Conditioning Intensity	Diag
Adult	3644210	2013	6/28/2013	2	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3859495	2013	1/11/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3863448	2013	1/23/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3867977	2013	1/22/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3878529	2013	2/5/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3879477	2013	1/31/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3879634	2013	2/7/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3881192	2013	2/1/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3881200	2013	2/20/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3889054	2013	3/8/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3890565	2013	3/12/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3892124	2013	2/27/2013	1	Allogeneic	Unrelated Donor	1 Antigen Mismatch	Myeloablative	AML
Adult	3898782	2013	3/19/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3903012	2013	4/2/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3906130	2013	4/5/2013	1	Allogeneic	Unrelated Donor	1 Antigen Mismatch	Non-Myeloablative	AML
Adult	3909845	2013	3/26/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3911387	2013	4/12/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3913128	2013	4/16/2013	1	Allogeneic	Unrelated Donor	1 Antigen Mismatch	Myeloablative	AML
Adult	3914993	2013	4/19/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3932557	2013	4/11/2013	1	Allogeneic	Related Donor	≥ 1 Antigen Mismatch	Non-Myeloablative	AML
Adult	3936319	2013	5/10/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3939123	2013	5/17/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3939388	2013	5/17/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3949692	2013	6/5/2013	1	Allogeneic	Unrelated Donor	1 Antigen Mismatch	Myeloablative	AML
Adult	3951532	2013	1/15/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3958230	2013	6/18/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3963933	2013	6/25/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3983279	2013	7/23/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	3983352	2013	7/23/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	3997865	2013	8/13/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	4009249	2013	8/28/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	4009314	2013	8/27/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	4023851	2013	9/26/2013	1	Allogeneic	Related Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	4028579	2013	10/2/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Adult	4034429	2013	10/10/2013	1	Allogeneic	Related Donor	≥ 1 Antigen Mismatch	Non-Myeloablative	AML
Adult	4043933	2013	10/17/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Adult	4046332	2013	10/23/2013	1	Allogeneic	Unrelated Donor	0 Antigen Mismatch	Non-Myeloablative	AML

* CIBMTR does not use "antigen" level typing as indicated on the RFI, but uses "Allele" level typing to determine HLA match grade.

* Caution: This application allows you to view data that you have provided to CIBMTR. CIBMTR does not collect every variable required for your RFI submission, for example, CIBMTR does not collect length of stay or lost to follow up. Discrepancies in RFI data can only be determined and corrected by the center. Centers are strongly encouraged to review this data for accuracy and completeness before using these data for inclusion in the RFI.

[Compatibility Mode] - Excel

File Home Insert Page Layout Formulas Data Review View Tell me what you want to do

Cut Copy Paste Format Painter Clipboard

Arial 12 A A

B I U Merge & Center

Wrap Text

General

Conditional Formatting Table

Normal Neutral

A1

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
10			100 day survival				49	98%	57	100%	54	89%	160	95%	21	48%		
11			1 year survival				43	86%	46	81%	26	43%	115	68%				
12			Lost to follow-up < 100 days															
13			Lost to follow-up between 100 days and 1 year															
14			2) Length of Stay															
15			Average in days															
16			Median in days															
17																		
18																		
19																		
20			Allogeneic Myeloablative Related Donor				2013		2014		2015		Cumulative 2013-2015		2016 (thru 9/30/16)			
21			0 Antigen Mismatch				#	%	#	%	#	%	#	%	#	%		
22			1) Survival Statistics															
23			Total Patients				20		17		19		56		17			
24			100 day survival				20	100%	17	100%	16	84%	53	95%	5	29%		
25			1 year survival				14	70%	15	88%	3	16%	32	57%				
26			Lost to follow-up < 100 days															
27			Lost to follow-up between 100 days and 1 year															
28			2) Length of Stay															
29			Average in days															
30			Median in days															
31																		
32																		
33																		
34			Allogeneic Myeloablative Related Donor				2013		2014		2015		Cumulative 2013-2015		2016 (thru 9/30/16)			
35			≥ 1 Antigen Mismatch				#	%	#	%	#	%	#	%	#	%		
36			1) Survival Statistics															
37			Total Patients				0		6		8		14		3			
38			100 day survival				0	0%	6	100%	7	88%	13	93%	2	67%		
39			1 year survival				0	0%	4	67%	0	0%	4	29%				
40			Lost to follow-up < 100 days															
41			Lost to follow-up between 100 days and 1 year															
42			2) Length of Stay															
43			Average in days															
44			Median in days															
45																		
46																		
47																		
48																		

Page 1

Definitions adult clinical statistics adult survival by disease pediatric clinical statistics pediatric survival by disease ...

Ready

What are the limitations?

- Uses "Allele" level typing to determine HLA match grade, not "antigen" level as indicated on the RFI.
- Survival calculations based on ASBMT specifications.

What are the limitations?

- Caution:
 - Only uses data provided to CIBMTR.
 - Only uses variables collected by CIBMTR. No LOS.
 - Centers must reconcile discrepancies in RFI data can only be determined and corrected by the center.
 - Centers are strongly encouraged to review this data for accuracy and completeness before using these data for inclusion in the RFI.

ASBMT RFI Patient Level Data

Search

eDBtC

Current Selections



Clear All Selections

Adult-Pediatric Indicator
Adult

Transplant Type
Allogeneic
Autologous

Diagnosis
AML and ALL
CLL
CML
Hodgkin's Disease
MDS
Myeloma/PCD
Neuroblastoma

Transplant Not Counted Reason
Missing HLA-Matching
Unknown Risk
Unknown Risk; Missing Donor Type; Missing Conditionin...
Unknown Risk; Missing HLA-Matching

RFI Patient Level Data

Adult-Pediatric Indicator	CRID	Year of Transplant	Transplant Date	Transplant Number	Transplant
Adult	3644210	2013	6/28/2013	2	Allogeneic
Adult	3859495	2013	1/11/2013	1	Allogeneic
Adult	3863448	2013	1/23/2013	1	Allogeneic
Adult	3867977	2013	1/22/2013	1	Allogeneic
Adult	3878529	2013	2/5/2013	1	Allogeneic
Adult	3879477	2013	1/31/2013	1	Allogeneic
Adult	3879634	2013	2/7/2013	1	Allogeneic
Adult	3881192	2013	2/1/2013	1	Allogeneic
Adult	3881200	2013	2/20/2013	1	Allogeneic
Adult	3889054	2013	3/8/2013	1	Allogeneic
Adult	3890565	2013	3/12/2013	1	Allogeneic
Adult	3892124	2013	2/27/2013	1	Allogeneic
Adult	3898782	2013	3/19/2013	1	Allogeneic
Adult	3903012	2013	4/2/2013	1	Allogeneic
Adult	3906130	2013	4/5/2013	1	Allogeneic
Adult	3909845	2013	3/26/2013	1	Allogeneic
Adult	3911387	2013	4/12/2013	1	Allogeneic
Adult	3913128	2013	4/16/2013	1	Allogeneic
Adult	3914993	2013	4/19/2013	1	Allogeneic
Adult	3932557	2013	4/11/2013	1	Allogeneic
Adult	3936319	2013	5/10/2013	1	Allogeneic
Adult	3939123	2013	5/17/2013	1	Allogeneic
Adult	3939388	2013	5/17/2013	1	Allogeneic
Adult	3949692	2013	6/5/2013	1	Allogeneic
Adult	3951532	2013	1/15/2013	1	Allogeneic
Adult	3958230	2013	6/18/2013	1	Allogeneic
Adult	3963933	2013	6/25/2013	1	Allogeneic
Adult	3983279	2013	7/23/2013	1	Allogeneic
Adult	3983352	2013	7/23/2013	1	Allogeneic
Adult	3997865	2013	8/13/2013	1	Allogeneic
Adult	4009249	2013	8/28/2013	1	Allogeneic
Adult	4009314	2013	8/27/2013	1	Allogeneic
Adult	4023851	2013	9/26/2013	1	Allogeneic
Adult	4028579	2013	10/2/2013	1	Allogeneic
Adult	4034429	2013	10/10/2013	1	Allogeneic
Adult	4043933	2013	10/17/2013	1	Allogeneic
Adult	4046332	2013	10/23/2013	1	Allogeneic

ASBMT RFI Export

Caution: This application allows you to extract data that you have provided to CIBMTR in a manner that is consistent with the format of the current RFI report. Data extracted here is NOT intended as a submission report, as the CIBMTR does not collect every variable required for your RFI submission, for example, CIBMTR does not collect length of stay or lost to follow up. Discrepancies in RFI data can only be determined and corrected by the center. Centers are strongly encouraged to review these data for accuracy and completeness before using data in this extract for inclusion in the RFI.

OK

Cancel

Related Donor	Antigen Mismatch	Myeloablative	AML
Unrelated Donor	1 Antigen Mismatch	Myeloablative	AML
Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Related Donor	0 Antigen Mismatch	Myeloablative	AML
Unrelated Donor	1 Antigen Mismatch	Non-Myeloablative	AML
Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Unrelated Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Unrelated Donor	1 Antigen Mismatch	Myeloablative	AML
Related Donor	0 Antigen Mismatch	Myeloablative	AML
Related Donor	≥ 1 Antigen Mismatch	Non-Myeloablative	AML
Related Donor	0 Antigen Mismatch	Myeloablative	AML
Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Related Donor	0 Antigen Mismatch	Myeloablative	AML
Unrelated Donor	1 Antigen Mismatch	Myeloablative	AML
Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Related Donor	0 Antigen Mismatch	Myeloablative	AML
Related Donor	0 Antigen Mismatch	Non-Myeloablative	AML
Related Donor	0 Antigen Mismatch	Myeloablative	AML
Related Donor	0 Antigen Mismatch	Myeloablative	AML
Unrelated Donor	1 Antigen Mismatch	Non-Myeloablative	AML
Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML
Unrelated Donor	0 Antigen Mismatch	Myeloablative	AML

* CIBMTR does not use "antigen" level typing as indicated on the RFI, but uses "Allele" level typing to determine HLA match grade.

* Caution: This application allows you to view data that you have provided to CIBMTR. CIBMTR does not collect every variable required for your RFI submission, for example, CIBMTR does not collect length of stay or lost to follow up. Discrepancies in RFI data can only be determined and corrected by the center. Centers are strongly encouraged to review this data for accuracy and completeness before using these data for inclusion in the RFI.

Caution – Data Extract

- This application allows you to extract data that you have provided to CIBMTR in a manner that is consistent with the format of the current RFI report.
- Data extracted here is **NOT** intended as a submission report, but rather to inform that report!

Epic BMT User Group

- Formed January 2014; inaugural meeting at Tandem 2014
- Monthly WebEx teleconference calls and annual in-person meeting at Tandem
- Roster currently represents over 20 BMT centers using Epic in the US
- Chairs: Doug Rizzo (CIBMTR/MCW), Vincent Ho (DFCI)
- Epic team: Brendan Iglehart, Sashi Bellam

New Chronic GVHD Flowsheet

File Add Rows Add_LDA Cascade Add_Col Insert Col Last Filed Reg Doc Graph

Amb Complex Vitals Nav Toxicity Assess Screenings **Chronic GVHD** Chronic GVHD

Accordion Expanded **View All**

Appointment fr...
2/9/17
1300

Performance Score

Karnofsky Score	60
ECOG Score	2

Chronic GVHD Presence

Has chronic GVHD developed since the last entry?	Yes
Date Of Chronic GVHD Diagnosis	
Is there persistence of chronic GVHD since the last entry?	
Has biopsy for chronic GHVD been resulted since last entry?	

Skin - Skin Features Scoring

Sclerotic features?	
Skin Features Score	

Skin - Other Non-BSA-Calculated GVHD Features

Hyperpigmentation?	
Hypopigmentation?	
Poikiloderma?	
Severe Or Generalized Pruritus?	
Hair involvement?	
Nail Involvement?	

Skin - Non-GVHD attribution

Is the above attributable ENTIRELY to a non-GVHD cause?	
---	--

Overall Chronic GVHD Severity

Chronic GVHD Global Severity Score	
Subjective Clinician Opinion Of Severity	

Flowsheets view

Chronic GVHD - Chronic GVHD

Time taken: 1511 2/7/2017 Show: Row Info Last Filed Details All Choices

Responsible + Create Note

Performance Score

Karnofsky Score 100=Normal, no complaints, no evidence of disease

ECOG Score

Chronic GVHD Presence

Has chronic GVHD developed since the last entry? Yes No Unknown

Date Of Chronic GVHD Diagnosis

Is there persistence of chronic GVHD since the last entry? Yes No Unknown

Has biopsy for chronic GHVD been resulted since last entry? Yes No Unknown Not Done Not Appli...

Skin - Other Non-BSA-Calculated GVHD Features

Hyperpigmentation? Yes No

Hypopigmentation? Yes No

Poikiloderma? Yes No

Severe Or Generalized Pruritus? Yes No

Hair involvement? Yes No

Nail Involvement? Yes No

Skin - Non-GVHD attribution

Is the above attributable ENTIRELY to a non-GVHD cause? Yes No

Overall Chronic GVHD Severity

Chronic GVHD Global Severity Score

Subjective Clinician Opinion Of Severity Mild Moderate Severe

Navigator view



Questions?



Center Specific Survival Analysis Methods



The CIBMTR[®] (Center for International Blood and Marrow Transplant Research[®]) is a research collaboration between the National Marrow Donor Program[®] (NMDP)/Be The Match[®] and the Medical College of Wisconsin (MCW).

Center Outcomes Analysis:

Basic Concepts

- Examination of individual center specific outcomes relative to the overall network
 - The CENTER is the unit of analysis
- Risk Adjustment for relevant patient, disease, transplant factors ('case mix')
- Assessment of center performance needs to account for sampling variability/sample size
- Understandable to public audience

Statistical Methods (abbreviated)

- First allogeneic HCT only
- Observed survival probability: Kaplan-Meier estimates of one year survival, by center
- Predicted survival probability (Risk adjustment):
 - **Multivariate modeling** accounts for the types of patients being transplanted at the center
 - Fixed effects censored data logistic regression model allows for incomplete follow-up (within reason)
 - Includes calculation of 95% confidence limits around the predicted survival probability
- Comparison of the observed to the 95% CI of the predicted survival probability in each center

Statistical Methods (abbreviated)

- Predicted survival outcome at a given center is based on the average predicted survival of patients actually transplanted at that center
 - Directly comparable to unadjusted K-M estimate to assess center performance
- This represents what we would have expected to happen to the patients at that center if they had been transplanted at a “generic” center in the network (i.e. no center effect)
- Need to account for sampling variability in comparing observed and predicted outcomes
 - Confidence limits built from predicted survival estimates

Significant Risk Factors

- Patient:
 - Race of recipient
 - Recipient Age*
 - Recipient CMV status
 - Year of HCT
 - Karnofsky/Lansky perf. Score*
 - HCT-CI
 - Co-existing disease
- Disease (con't)
 - Disease and stage*
 - NHL subtype
 - Disease sensitivity (NHL and HL only)
 - Time from dx to tx (ALL and AML not in CR1/PIF only)
- Transplant:
 - Donor type/graft type and HLA
 - Donor Age
 - Donor/recipient sex match
 - Prior autoHCT
 - Conditioning regimen intensity